The Midwest Reproductive Symposium and SRxA Enter Into an Exclusive Publications Collaboration
Washington, DC, March 25, 2011 --(PR.com)-- SRxA Strategic Pharmaceutical Advisors, a leading healthcare consulting, marketing and education firm, is pleased to announce that it has entered into an agreement with the Executive Directors and organizers of the Midwest Reproductive Symposium (MRS) and Fertility Centers of Illinois (FCI), to become the exclusive provider of rapid dissemination post-congress e-newsletters.
The MRS is an annual educational program started in 2005 to promote the timely discussion of issues relevant to reproductive medicine. Today, the MRS is internationally recognized as a program of excellence, providing the most up-to-date information on clinical and research topics of current interest, and sometimes, controversial. The MRS offers attendees a unique opportunity to network with faculty and colleagues in casual and formal educational venues. Sessions and workshops during the 2-day program are designed for maximal interaction; a REI Fellows Poster Session is included; and a Nurse Practicum Day – developed by nurses for nurses – precedes the meeting.
The 2011 MRS is scheduled for June 9-11 at the Drake Hotel, Chicago. Attendance is limited to 250. However, in recent years, more than 250 physicians, nurses, embryologists, psychologists, and other health care professionals have expressed interest in the program. In response, the Executive Committee is pursuing several options for disseminating information from and about the meeting,
To this end, SRxA and its team of Reproductive Health Advisors will develop, produce and distribute an interactive e-newsletter within four weeks of the Symposium. The e-newsletter will feature a blend of scientific session reviews, “hot topic” discussions, key takeaway messages, news from the exhibit hall, and other pertinent information. This will be distributed electronically to more than 10,000 US-based health professionals and scientists in reproductive medicine.
Publication and distribution of the e-newsletter will include the support of multiple pharmaceutical and device industry sponsors, who will be prominently acknowledged. Sponsorship efforts are ongoing.
“This electronic newsletter will enable us to reach a much wider audience than we have previously been able to address due to the capacity of the live event. It will be a perfect complement to the program and will provide both attendees and non-attendees with a true flavor of the MRS. SRxA was the natural choice for a partner in this endeavor because of the depth of their knowledge and expertise in Reproductive Health and their unique ability to produce informative and intriguing peer-reviewed, rapid electronic publications following scientific congresses,” said Dr. Angeline Beltsos, MRS Chairperson and FCI Medical Director.
“We are delighted to work with Dr. Beltsos and her team to develop and produce a unique vehicle that will distribute pertinent information in a timely fashion to the medical communities they serve,” commented Christos Efessiou, PhD, SRxA’s Chief Executive Officer.
SRxA operates on a unique business model that utilizes independent clinical teams of national and international Key Opinion Leaders who advise pharmaceutical and medical device clients in research, clinical, regulatory, education and business matters. SRxA advisory groups focus in key therapeutic areas such as Allergy, Otolaryngology, Pulmonary Diseases, Respiratory Medicine (Europe), Ophthalmology, Health Outcomes, Reproductive Endocrinology and Genetics, Aesthetics, and Behavioral Health. The company is headquartered in Washington, DC with offices in London and Hong Kong. For more information, please contact Judi Miller at 202.316.8692, jmiller@SRxA.com, or visit www.srxa.com.
Fertility Centers of Illinois, S.C., (FCI), founder and host organization of the MRS, is one of the nation’s leading infertility treatment practices, providing advanced reproductive endocrinology services in the Chicago area for more than 30 years. Offering some of the most sophisticated reproductive technology services currently available, FCI is one of a handful of referral centers for advanced genetic and fertility treatments. FCI is part of IntegraMed, the nation’s largest and most reputable network of fertility centers.
Contact
Judi Miller
202.316.8692
jmiller@SRxA.com
###
The MRS is an annual educational program started in 2005 to promote the timely discussion of issues relevant to reproductive medicine. Today, the MRS is internationally recognized as a program of excellence, providing the most up-to-date information on clinical and research topics of current interest, and sometimes, controversial. The MRS offers attendees a unique opportunity to network with faculty and colleagues in casual and formal educational venues. Sessions and workshops during the 2-day program are designed for maximal interaction; a REI Fellows Poster Session is included; and a Nurse Practicum Day – developed by nurses for nurses – precedes the meeting.
The 2011 MRS is scheduled for June 9-11 at the Drake Hotel, Chicago. Attendance is limited to 250. However, in recent years, more than 250 physicians, nurses, embryologists, psychologists, and other health care professionals have expressed interest in the program. In response, the Executive Committee is pursuing several options for disseminating information from and about the meeting,
To this end, SRxA and its team of Reproductive Health Advisors will develop, produce and distribute an interactive e-newsletter within four weeks of the Symposium. The e-newsletter will feature a blend of scientific session reviews, “hot topic” discussions, key takeaway messages, news from the exhibit hall, and other pertinent information. This will be distributed electronically to more than 10,000 US-based health professionals and scientists in reproductive medicine.
Publication and distribution of the e-newsletter will include the support of multiple pharmaceutical and device industry sponsors, who will be prominently acknowledged. Sponsorship efforts are ongoing.
“This electronic newsletter will enable us to reach a much wider audience than we have previously been able to address due to the capacity of the live event. It will be a perfect complement to the program and will provide both attendees and non-attendees with a true flavor of the MRS. SRxA was the natural choice for a partner in this endeavor because of the depth of their knowledge and expertise in Reproductive Health and their unique ability to produce informative and intriguing peer-reviewed, rapid electronic publications following scientific congresses,” said Dr. Angeline Beltsos, MRS Chairperson and FCI Medical Director.
“We are delighted to work with Dr. Beltsos and her team to develop and produce a unique vehicle that will distribute pertinent information in a timely fashion to the medical communities they serve,” commented Christos Efessiou, PhD, SRxA’s Chief Executive Officer.
SRxA operates on a unique business model that utilizes independent clinical teams of national and international Key Opinion Leaders who advise pharmaceutical and medical device clients in research, clinical, regulatory, education and business matters. SRxA advisory groups focus in key therapeutic areas such as Allergy, Otolaryngology, Pulmonary Diseases, Respiratory Medicine (Europe), Ophthalmology, Health Outcomes, Reproductive Endocrinology and Genetics, Aesthetics, and Behavioral Health. The company is headquartered in Washington, DC with offices in London and Hong Kong. For more information, please contact Judi Miller at 202.316.8692, jmiller@SRxA.com, or visit www.srxa.com.
Fertility Centers of Illinois, S.C., (FCI), founder and host organization of the MRS, is one of the nation’s leading infertility treatment practices, providing advanced reproductive endocrinology services in the Chicago area for more than 30 years. Offering some of the most sophisticated reproductive technology services currently available, FCI is one of a handful of referral centers for advanced genetic and fertility treatments. FCI is part of IntegraMed, the nation’s largest and most reputable network of fertility centers.
Contact
Judi Miller
202.316.8692
jmiller@SRxA.com
###
Contact
SRxA Strategic Pharmaceutical Advisors, LLC
Judi Miller
202.316.8692
www.srxa.com
Judi Miller
202.316.8692
www.srxa.com
Contact
Categories